Creating a dementia-free society through food and science
Creating a dementia-free society through food and science
About us
Our Research Philosophy
Empowering a society that prevents dementia through nutrition and science.
As the global population continues to age, the number of people living with dementia is steadily rising. In Japan alone, recent studies show that 4.71 million people aged 65 and over were living with dementia in 2025, a number lower than earlier projections but still deeply concerning. Despite this revision, long‑term research consistently indicates that around one in five people aged 65 and over will develop dementia in the mid‑2020s, and prevalence is expected to continue climbing in the years ahead. The social impact of dementia is profound. Medical and long‑term care costs continue to grow, while families and caregivers face immense emotional and economic pressure. Current medical approaches still find it extremely difficult to restore cognitive function once dementia has developed, making treatment a challenge and recovery unlikely. That is why prevention—reducing risk before the disease begins—is more essential than ever. At our core, we are committed to building a society where individuals can take charge of their own well‑being through daily self‑care supported by food and science. We believe in empowering people with accessible, science‑based solutions that protect cognitive health and help shape a future where dementia is no longer an unavoidable part of aging.
Technology
Scientific Research and Development
Seizing the moment of intervention to transform dementia care.
Capture the timing of the intervention, Change the common sense of dementia treatment.
Cerebro Pharma was founded in November 2017 as a venture originating from Osaka City University (now Osaka Metropolitan University). The company is built upon the pioneering research of Professor Tomiyama, who led the university’s Department of Dementia Pathophysiology at the Graduate School of Medicine. Our mission is to develop and deliver preventive and therapeutic drugs for dementia based on these scientific achievements. One of the primary reasons many dementia drug candidates have failed in clinical trials is that intervention has come too late. The key is to remove toxic amyloid‑β and tau oligomers before neuronal death begins. To achieve this goal, we collaborate deeply with academia as we work to establish a foundational preventive approach to dementia and ensure its adoption in society.
Cerebro Pharma leverages foundational research elucidating the molecular and cellular mechanisms of aging and converts these findings into scientifically validated supplement formulations. By applying our innovative translational approach, we aim to promote cognitive and systemic health, enabling individuals to sustain high levels of function, autonomy, and well‑being.
Department of Geriatrics and Dementia Control, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahimachi, Abeno-ku, Osaka-shi, Osaka 545-8585 Japan
164,500,000 yen (Capital Reserve: 152,500,000 yen)
Representative Director
Takami Tomiyama Matsuda Kazunori
Officers
Director Takaaki Fukunaga Director Junki Nishimura Director Yasuo Izumi Auditor Kiyohara Dai
Obtain Approval
Our company is certified according to the international standard “ISO/IEC 27001:2022” for information security management. ISMS certification registration number: GIJP-1945-IC
Recruit
Recruiting Information
To stay youthful, healthy, and beautiful
At Cerebro Pharma, we bring scientific insight into everyday lifestyle habits, creating a new approach to self‑care. And for a future where the people you cherish can keep smiling, we invite you to join us in delivering a new kind of value to society - “proactive prevention” that challenges conventional wisdom.
